Shanghai Medicilon Inc. (SHA:688202)
China · Delayed Price · Currency is CNY 107.64
+3.68 (3.54%)
At close: Sep 30, 2026
Shanghai Medicilon Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,384 | 1,163 | 1,038 | 1,366 | 1,659 | 1,167 |
Revenue Growth | 30.98% | 12.08% | -24.01% | -17.68% | 42.12% | 75.28% |
Gross Profit Gross Profit Growth | 321.45 | 192.53 | 30.04 | 305.74 | 675.36 | 527.76 |
Operating Income Operating Income Growth | -106.45 | -184.78 | -371.8 | -84.17 | 322.6 | 308.47 |
Net Income Net Income Growth | -103.33 | -167.83 | -330.85 | -33.21 | 338.24 | 282.22 |
Earnings Per Share EPS Growth | -0.77 | -1.27 | -2.47 | -0.26 | 2.78 | 2.32 |
EPS Growth | - | - | - | - | 19.75% | 117.71% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Drug Discovery and Pharmaceutical Research Drug Discovery and Pharmaceutical Research Growth | 651.95 | 573.03 | 495.07 | 631.8 | 735.24 | 612.97 |
Preclinical Study Preclinical Study Growth | 732.09 | 589.91 | 542.21 | 733.8 | 923.63 | 553.53 |
Total Total Growth | 1,384 | 1,163 | 1,037 | 1,366 | 1,659 | 1,167 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 554.78 | 567.03 | 700.52 | 990.1 | 197.13 | 512.37 |
Total Debt Total Debt Growth | 222.71 | 247.44 | 346.08 | 382.88 | 274.9 | 43.56 |
Net Cash (Debt) Net Cash Growth | 332.07 | 319.59 | 354.44 | 607.22 | -77.76 | 468.8 |
Net Cash Growth | 8.27% | -9.83% | -41.63% | - | - | 0.61% |
Net Cash Per Share Net Cash Per Share Growth | 2.48 | 2.42 | 2.65 | 4.75 | -0.64 | 3.86 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 165.3 | 105.17 | -22.75 | 33.32 | -21.33 | 452.94 |
Capital Expenditures CapEx Growth | -147.51 | -69.03 | -110.39 | -185.68 | -404.06 | -292.71 |
Free Cash Flow Free Cash Flow Growth | 17.79 | 36.14 | -133.14 | -152.36 | -425.39 | 160.22 |
Free Cash Flow Growth | -56.07% | - | - | - | - | 79.93% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 23.22% | 16.55% | 2.90% | 22.39% | 40.71% | 45.21% |
Operating Margin | -7.69% | -15.89% | -35.83% | -6.16% | 19.45% | 26.43% |
Pretax Margin | -8.01% | -15.91% | -36.72% | -4.33% | 22.19% | 27.66% |
Profit Margin | -7.46% | -14.43% | -31.88% | -2.43% | 20.39% | 24.18% |
FCF Margin | 1.29% | 3.11% | -12.83% | -11.16% | -25.64% | 13.73% |
| Fiscal Year | FY 2022 | FY 2021 |
|---|---|---|
| Period Ending | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.279 | 0.699 |
Dividend Per Share Growth | -60.14% | 117.49% |
Dividend Yield | 0.18% | 0.28% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 55.03 | 106.81 |
Forward PE | - | 18.74 | 17.14 | 44.40 | 100.83 | 100.83 |
P/FCF Ratio | 795.77 | 205.29 | - | - | - | 188.15 |
PS Ratio | 10.23 | 6.38 | 3.89 | 6.74 | 11.22 | 25.83 |